
ELAN Stock Forecast & Price Target
ELAN Analyst Ratings
Bulls say
Elanco Animal Health has established a strong market presence with Simparica Trio, holding over 50% of the market share, while the anticipated growth of Credelio Quattro from 12.8% to an estimated 16.8% by 2026 indicates robust potential in the companion animal segment. The company’s Advantage Family and Seresto products have demonstrated impressive year-over-year growth of 33% and 28%, respectively, in the third quarter of 2025, reflecting consistent demand and performance improvement. These leading market shares and strong growth metrics position Elanco favorably for continued success in the competitive animal health industry.
Bears say
Elanco Animal Health is facing significant financial challenges as its EBITDA margin has deteriorated despite a 50% increase in revenue, impacting overall profitability. Additionally, concerns regarding refinancing risks have emerged, following Dentsply Sirona's recent bond offering, which could potentially hinder Elanco's earnings growth in 2026. The company’s financial outlook remains precarious, compounded by lower margins and looming refinancing needs, suggesting a negative trajectory in the near term.
This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELAN Analyst Forecast & Price Prediction
Start investing in ELAN
Order type
Buy in
Order amount
Est. shares
0 shares